NJ-RUNPOD
8.5.2024 15:08:27 CEST | Business Wire | Press release
RunPod, the launchpad that empowers developers to deploy custom full-stack AI applications, today announced it raised $20M in Seed funding, co-led by Intel Capital and Dell Technologies Capital with participation from Julien Chaummond, Nat Friedman, and Adam Lewis. In conjunction with the financing, Mark Rostick, Vice President and Senior Managing Director at Intel Capital, will join RunPod’s board of directors.
RunPod is a globally distributed GPU cloud computing service for training, deploying, and scaling AI models. Using RunPod’s two core products, GPU Cloud and Serverless, developers can spin up an on-demand GPU instance in a few clicks and create autoscaling API endpoints for scaling inference on AI models in production.
“The ability to create and deploy AI applications at scale will be paramount to their adoption and utilization,” said Amjad Masad, RunPod investor. “The RunPod team has clearly prioritized the developer experience to create an elegant solution that enables individuals to rapidly develop custom AI apps or integrations while also paving the way for organizations to truly deliver on the promise of AI.”
RunPod makes it simple for developers to seamlessly run any GPU workload, allowing them to focus less on Machine Learning operations and more on building their applications. These capabilities have proven advantageous to developers and resulted in RunPod’s swift expansion with 10-fold revenue growth year over year.
“RunPod started as a playground for developers and innovators, a place where they went to do their research, develop and finetune their projects; now, it boasts a community of over 100K developers,” said Zhen Lu, co-founder and CEO of RunPod. “We’ve grown so quickly because RunPod strikes the perfect balance between providing developers with the freedom to launch whatever they want, while still having the necessary infrastructure and tools in place to assist in the customization, development, and deployment of differentiated products.”
The emergence of AI-specific workloads has given rise to increased computational demands. Once the go-to solution, out-of-the-box cloud infrastructure platforms are no longer cost-effective or fast enough to create custom-differentiated products. With RunPod, developers can reliably and simply develop, train, scale, and launch custom full-stack AI applications or integrations in the cloud on a global scale.
“RunPod is rapidly growing both its customer base and revenue by offering a broad, fast, and easy-to-use platform that meets the needs of developers and their model-based applications," said Mark Rostick, Vice President and Senior Managing Partner at Intel Capital. “I’ve watched RunPod’s momentum scale from a small startup offering individual developers an ecosystem to kickstart their research and development to a serverless offering that allows enterprise customers to scale their customized high-grade products and solutions.”
Rapid growth and developer adoption created the need to grow the team almost 10x in the past year, establishing itself as a leader pioneering GPU AI-powered transformation. The platform has recently launched the ability to deploy CPU compute instances, a huge milestone in creating a holistic cloud solution. This Seed funding will enable RunPod to enhance the day-to-day life of developers, form new partnerships and integrations for seamless user experiences, and offer new and existing customers the perfect foundation for developing custom AI models.
“As the enterprise deploys more AI applications into production, the key to their success is access to fast, reliable, and scalable infrastructure. This is what Zhen, Pardeep, and the team have built with the RunPod platform,” said Radhika Malik, Partner at Dell Technologies Capital. “They are committed to keeping the dev experience central to everything they do. That’s resulted in overwhelmingly positive sentiment from the community and impressive, sustained user growth.”
About RunPod:
RunPod is a globally distributed GPU cloud platform that empowers developers to deploy custom full-stack AI applications – simply, globally, and at scale. With RunPod’s key offerings, GPU Instances and Serverless GPUs, developers can develop, train and scale AI applications in one cloud within seconds. RunPod is committed to making cloud computing accessible and affordable without compromising features, usability, or experience. It strives to empower individuals and enterprises with cutting-edge technology, enabling them to unlock the potential of AI and cloud computing. To learn more about RunPod, visit https://www.runpod.io/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508053225/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
Roboverse Reply Impresses at ELROB 2026 With Intelligent Robotic Systems for Critical Missions26.6.2026 10:00:00 CEST | Press release
Roboverse Reply, the Reply Group company specializing in robotics and automation, won the 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial (ELROB) 2026 in Thun, Switzerland. Teaming up with ELP, a specialist for technical equipment for defusing service, the company demonstrated outstanding performance alongside a field of international participants from June 15 to 19, proving that its autonomous solutions operate reliably under real-world conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626012237/en/ Roboverse Reply won 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial 2026, proving that its autonomous solutions operate reliably under real-world conditions. ELROB is Europe’s most demanding and established showcase for robotics and unmanned systems, where leading experts from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
